AlphaCentric Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

AlphaCentric Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$350K	Buy	+491	New	+$412K	0.35%	85
2021 Q4	–	Sell	-400	Closed	-$242K	–	264
2021 Q3	$242K	Sell	400 -1,650	-80%	-$1.02M	0.06%	104
2021 Q2	$1.15M	Sell	2,050 -750	-27%	-$380K	0.31%	17
2021 Q1	$1.32M	Buy	2,800 +1,500	+115%	+$730K	0.45%	10
2020 Q4	$628K	Buy	1,300 +1,180	+983%	+$637K	0.26%	23
2020 Q3	$67K	Buy	+120	New	+$72.8K	0.03%	89

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlphaCentric Advisors's REGN Position: Q4 2024 in Review

AlphaCentric Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2024: 491 shares worth $350K. The stake represents 0.35% of the portfolio and ranks #85 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in REGN as recently as Q3 2021.

AlphaCentric Advisors first reported a position in REGN in Q3 2020 and has held it in 6 quarters since. The position peaked at $1.32M in Q1 2021. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

AlphaCentric Advisors held 491 shares of Regeneron Pharmaceuticals worth $350K as of Q4 2024.
Regeneron Pharmaceuticals was a new AlphaCentric Advisors position in Q4 2024.
Regeneron Pharmaceuticals made up 0.35% of AlphaCentric Advisors's portfolio in Q4 2024, its #85 holding.
AlphaCentric Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 6 quarters since.
AlphaCentric Advisors's Regeneron Pharmaceuticals position peaked at $1.32M in Q1 2021.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.